



File No. BIO/CT/23/000034

Dated 06-09-2023

To,

M/s Reliance Life Sciences Pvt Ltd ,
Dhirubhai Ambani Life Sciences Center, R-282 TTC Area of MIDC,
Thane -Belapur Road, Rabale Navi Mumbai (India) – 400701

Subject: Application for grant of permission to conduct Phase IV clinical trial entitled – "A prospective, multi-centre, open label, phase IV study to evaluate safety and efficacy profile of DenosteRel® in post-menopausal women with osteoporosis" as per Protocol No.: RLS/PMS/2022/06; Version 1.0, Dated: 01 Feb 2023- regarding

Ref. No.: Your Application No. BIO/CT04/FF/2023/36473 dated 13.03.2023

Sir,

With reference to your application No.: BIO/CT04/FF/2023/36473 dated 13.03.2023, please find enclosed herewith the permission in Form CT-06 for conduct of subject clinical trial under the provisions of New Drugs and Clinical Trial Rules, 2019.

The permission granted by the Central Licensing Authority to conduct clinical trial under this Chapter shall be subject to following conditions, namely:

- (I) Clinical trial at each site shall be initiated after approval of the clinical trial protocol and other related documents by the Ethics Committee of that site, registered with the Central Licensing Authority under rule 8
- (II) Where a clinical trial site does not have its own Ethics Committee, clinical trial at that site may be initiated after obtaining approval of the protocol from the Ethics Committee of another trial site; or an independent Ethics Committee for clinical trial constituted in accordance with the provisions of rule 7:
Provided that the approving Ethics Committee for clinical trial shall in such case be responsible for the study at the trial site or the centre, as the case may be:
Provided further that the approving Ethics Committee and the clinical trial site or the bioavailability and bioequivalence centre, as the case may be, shall be located within the same city or within a radius of 50 kms of the clinical trial site;
- (III) In case an ethics committee of a clinical trial site rejects the approval of the protocol, the details of the same shall be submitted to the Central Licensing Authority prior to seeking approval of another Ethics Committee for the protocol for conduct of the clinical trial at the same site;
- (IV) The Central Licensing Authority shall be informed about the approval granted by the Ethics Committee within a period of fifteen working days of the grant of such approval;
- (V) Clinical trial shall be registered with the Clinical Trial Registry of India maintained by the Indian Council of Medical Research before enrolling the first subject for the trial.
- (VI) Clinical trial shall be conducted in accordance with the approved clinical trial protocol and other related documents and as per requirements of Good Clinical Practices Guidelines and the provisions of these rules.

- (VII) Status of enrolment of the trial subjects shall be submitted to the Central Licensing Authority on quarterly basis or as appropriate as per the duration of treatment in accordance with the approved clinical trial protocol, whichever is earlier;
- (VIII) Six monthly status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Central Licensing Authority electronically in the SUGAM portal.
- (IX) In case of termination of any clinical trial the detailed reasons for such termination shall be communicated to the Central Licensing Authority within thirty working days of such termination.
- (X) Any report of serious adverse event occurring during clinical trial to a subject of clinical trial, shall, after due analysis, be forwarded to the Central Licensing Authority, the chairperson of the Ethics Committee and the institute where the trial has been conducted within fourteen days of its occurrence as per Table 5 of the Third Schedule and in compliance with the procedures as specified in Chapter VI.
- (XI) In case of injury during clinical trial to the subject of such trial, complete medical management and compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of the receipt of order issued by Central Licensing Authority in accordance with the provisions of the said Chapter.
- (XII) In case of clinical trial related death or permanent disability of any subject of such trial during the trial, compensation shall be provided in accordance with Chapter VI and details of compensation provided in such cases shall be intimated to the Central Licensing Authority within thirty working days of receipt of the order issued by the Central Licensing Authority in accordance with the provisions of the said Chapter.
- (XIII) The premises of the sponsor including his representatives and clinical trial sites, shall be open for inspection by officers of the Central Licensing Authority who may be accompanied by officers of the State Licensing Authority or outside experts as authorized by the Central Licensing Authority, to verify compliance of the requirements of these rules and Good Clinical Practices Guidelines, to inspect, search and seize any record, result, document, investigational product, related to clinical trial and furnish reply to query raised by the said officer in relation to clinical trial.
- (XIV) The laboratory owned by any person or a company or any other legal entity and utilised by that person to whom permission for clinical trial has been granted used for research and development, shall be deemed to be registered with the Central Licensing Authority and may be used for test or analysis of any drug for and on behalf of Central Licensing Authority.
- (XV) The Central Licensing Authority may, if considered necessary, impose any other condition in writing with justification, in respect of specific clinical trials, regarding the objective, design, subject population, subject eligibility, assessment, conduct and treatment of such specific clinical trial.
- (XVI) The sponsor and the investigator shall maintain the data integrity of the data generated during clinical trial.
- (XVII) It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug permission to market this drug in the country will automatically be granted to you.

RAJEEV SINGH
RAGHUVANSHI
(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Licensing Authority

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: cn=RAJEEV SINGH RAGHUVANSHI, o=DRUGS CONTROLLER
GENERAL, ou=RAJEEV SINGH RAGHUVANSHI, email=RAJEEV.SINGH.RAGHUVANSHI@GOV.IN,
2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c276904,
1015a06564fe67f54b765db1cb, postalCode=600034,
st=TAMIL NADU,
serialNumber=657F5E47D940985D8F03BDC902D0E1,
FE73CFA12A1A126EA94FAS701124A19013,
cn=RAJEEV SINGH RAGHUVANSHI

FORM CT-06

(See rules 22, 25, 26, 29 and 30)

PERMISSION TO CONDUCT CLINICAL TRIAL OF NEW DRUG OR INVESTIGATIONAL NEW DRUG

The Central Licensing Authority hereby permits M/s. M/s Reliance Life Sciences Pvt Ltd, Dhirubhai Ambani Life Sciences Center, R-282 TTC Area of MIDC, Thane -Belapur Road, Rabale Navi Mumbai (India) – 400701 to conduct Phase IV clinical trial entitled – **"A prospective, multi-centre, open label, phase IV study to evaluate safety and efficacy profile of DenosteRel® in post-menopausal women with osteoporosis"** as per Protocol No.: RLS/PMS/2022/06; Version 1.0, Dated: 01 Feb 2023 in the below mentioned clinical trial sites.

2. Details of new drug and clinical trial site [as per Annexure].
3. This permission is subject to the conditions prescribed in part A of Chapter V of the New Drugs and Clinical Trials Rules, 2019 under the Drugs and Cosmetics Act, 1940.
4. It may kindly be noted that merely granting permission to conduct clinical trial with the drug does not convey or imply that based on the clinical trial data generated with the drug permission to market this drug in the country will automatically be granted to you.

Place: New Delhi

Date: 06-Sep-2023

RAJEEV SINGH
RAGHUVANS
HI

(Dr. Rajeev Singh Raghuvanshi)
Drugs Controller General (India)
Central Licensing Authority

Digitally signed by RAJEEV SINGH RAGHUVANSHI
DN: c=IN, o=CENTRAL DRUGS STANDARD
CONTROL ORGANIZATION, ou=RAJEEV SINGH
RAGHUVANSHI,
2.5.4.20=80c62f6a23e4eafbe8a239774cdeb03c27
69041015a06564fe67f54b765db1cb,
postalCode=600034, st=TAMIL NADU,
serialNumber=657F5E47D940985D8F03BDC902D
0E1FE73CFA12A1A126EA94FA5701124A19013,
cn=RAJEEV SINGH RAGHUVANSHI
Date: 2023.09.11 10:11:36 +05'30'

Annexure:**Details of new drug or investigational new drug:**

Names of the new drug or investigational new drug:	Denosumab Injection 60mg/ml (r-DNA Origin) single use vial and PFS	
Therapeutic class	Monoclonal Antibody	
Dosage form:	1) Single dose prefilled syringe containing 60 mg in a 1 mL solution for subcutaneous Injection 2) Single dose vial containing 60 mg in a 1 mL solution for subcutaneous Injection	
Composition:	Each 1 mL vial contains:	
	Name of Ingredients	Quantity (per vial/PFS)
	Densoumab Drug Substance, In house	60 mg
	Sorbitol IP, Ph.Eur	47.0 mg (4.7%)
	Acetate IP, Ph.Eur	1.0 mg (17mM)
	Polysorbate 20, IP/USP	0.1 mg (0.01%)
	Water for injection (IP/USP/BP)	q.s. to 1 mL
	Note: Target pH 5.2. pH adjusted with sodium hydroxide to target pH of 5.2 (Range: pH 4.2 to 6.2)	
Indications:	For treatment of osteoporosis in post-menopausal women at high risk for fracture	

Details of clinical trial site:

S. No.	Name and Address of Clinical Trial Site	Ethics Committee Details	Name of Principal Investigator
1.	Sir Ganga Ram Hospital. Sir Ganga Ram hospital marg , Rajinder nagar, New Delhi 110060, India	Sir Gangaram Hospital Marg, Rajinder Nagar, New Delhi-110060, India EC Reg. No.: ECR/20/Inst/DL/2013/RR-19	Dr. Atul Kakar
2.	Chennai Meenakshi multispeciality hospital limited, old # 149, New # 70, Luz Church road, Mylapore, Chennai 600004, Tamil Nadu, India	Chennai meenakshi Multispeciality hospital Ethics Committee EC Reg. No.: ECR/516/Inst/TN/2014/RR-20	Dr. V. Krishnamurthy
3.	Department of Orthopedics, GSVM Medical College, Near Rawatpur Crossing, Kanpur-208002	Room No. 125, First Floor, GSVM Medical College, Swaroop Nagar, Kanpur - 208002, Uttar Pradesh India	Dr. Rohit Nath

		EC Reg. No.: ECR/680/Inst/UP/2014/RR-20	
4.	Sanjivani Super Speciality Hospital Pvt. Ltd., C/O, Clinical Research Department, 1, Uday Park Society, Nr. Sunrise Park, Vastrapur Ahmedabad-380015, Gujarat, India	Asian bariatrics and cosmetics PVT LTD Khyati multispeciality hospital S no. 235/2, B/s Tata motors showroom , opposite Rajpath club road , SG highway , Bodakdev , Ahmedabad 380015 ECR/698/Inst/GJ/2015/RR-21	Dr. Sharad Purohit
5.	Department of Orthopedics, Institute of Post Graduate Medical Education & Research, 244 AJC Bose Road, Kolkata-700020, West Bengal, India	IGPME&RSSKM Hospital , 244, AJC Bose road , bhowanipore , Kolkata , West Bengal -700020, India EC Reg. No. ECR/35/Inst/WB/2013/RR-19	Dr. Arnab Karmakar
6.	Department of Orthopedics, King George Medical University, RALC Campus, Nabiulla Road Lucknow-226018	Institutional ethics committee, research cell, Administrative block, King George Medical University, Chowk, Lucknow 226003 EC Reg No. ECR/262/Inst/Up/2013/RR-19	Dr. Shah Waliullah
7.	Dr. Vinod Kumar A C / Sunita Patil KIMS Hospital, Department of Orthopedics, B Block, OPD Building, K. R. Road, V. V. Puram, Bangalore-560004	KIMS Institutional Ethics Committee KIMS College Bsk 2nd Stage Bangalore 560070 Karnataka EC Reg No. ECR/1431/Inst/KA/2020	Dr. Vinod Kumar
8.	Room No. 75, 5 Floor, Dhanvantari OPD Block, SMS Hospital Jaipur-302016	Ethics Committee S.M.S. Medical College and Attached Hospitals J.L.N. Marg Jaipur Jaipur, Rajasthan -302004 India EC Reg No. ECR/26/Inst/RJ/2013/RR-19	Dr. Arunkumar Sharma
9.	Shlok Superspeciality Care, B/H Crescent Hotel Opp. Radhaswami Samyak, Lambhavel Road, Anand, Gujarat, India	Institutional Ethics Committee, Shlok Superspeciality Care, B/H Crescent Hotel Opp. Radhaswami Samyak, Lambhavel Road, Anand, Gujarat, India EC Reg No. ECR/1718/Inst/GJ/2022	Dr. Jeet Patel
10.	Medical College and Hospital, 88 College Street, Kolkata 700073, West Bengal, India	Institutional Ethics Committee for Human Research Medical College and Hospital Kolkata 88, college street , Kolkata 700073, West Bengal India EC Reg No. ECR/287/Inst/WB/2013/RR-19	Dr. Kaushik Basu

11.	AIIMS,Bhubaneswar, sujaa,Poatrapada,Po- Dumduma, Odisha, India,751019	Institutional Ethics CommitteeAIIMS,Bhubaneshwar , Sijua,patarpada,DumDuma,Odish a,India,751019 EC Reg No. ECR/534/Inst/OD/2014/RR-20	Dr. Sujata Devi
12.	Amber clinic 401-402 4th Floor, Santorini Square, Opp Star Bazar, behind Abhishree complex, Near Jodhpur Cross Rd, Satellite road, Ahmedabad -380015, Gujarat, India	Sangini Hospital Ethics CommitteeSangini Hospital, 1st floor and 708 (7th Floor), Santorini Square, Opp. Star Bazar Lane, b/h Abhishree complex Satellite, Ahmedabad- 380015, Gujarat, India Ahmadabad GUJARAT EC Reg No. ECR/147/Inst/GJ/2013/RR-19	Dr. Vishnu Sharma
13.	Oyster& Pearl Hospital,1671- 75,GaneshkhindRoad ,Shivaji nagr ,Pune,411005,Maharas htra India	O&P institutional Ethics CommitteeOyster & Pearl Hospital Phadnis Clinic Pvt.Ltd.,1671-75 Ganeshkhind Road Shivajinar Pune EC Reg No. ECR/71/Inst/MH/2013/RR-19	Dr. Rajesh Parasnis
14.	BJ Medical college and civil hospital, New Civil Hospital, Asarwa, Ahmedabad 380016	Institutional Ethics CommitteeB.J Medical college and civil hospital office of medical superintendent , Ahmdabad EC Reg No. ECR/72/Inst/GJ/2013/RR-19	Dr. Somesh Singh
15.	GMERS Medical College and Civil Hospital Sola, Nr Gujrat Highcourt, S.G. Highway, Sola, Ahmedabad, 380061, Gujrat, India	Institutional Ethics Committee GMERS Medical collegeGMERS Medical college and civil hospital,Sola Nr. Gujrat High court S.G Highway Sola Ahmedabad Gujarat EC Reg No. ECR/404/Inst/GJ/2013/RR-20	Dr. Bhavesh Jesalpura